Founded earlier this year to develop other firms’ candidates to intercept or prevent immune-mediated diseases, Provention Bio Inc. added its first two clinical candidates – both targeted at inflammatory bowel disease – by licensing a pair of candidates Sept. 21 from Janssen Pharmaceutica NV.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?